Health Condition 1: C969- Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Manipal academy of higher education
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients under 18 years 2. Diagnosed with Hematolymphoid malignancy 3. Prescribed with HDMTX regimen.
Exclusion criteria
Exclusion criteria: 1. Solid tumors and other hematological conditions 2. Not willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of adverse events throughout the HDMTX regimen will be identified, and the most and least occurring AE will be reported.Timepoint: Data collection will be carried out following the administration of high-dose methotrexate (HDMTX), specifically at the 24th and 42nd hours post-administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationship between serum MTX level and different patient, treatment, and disease-related characteristics, including the occurrence of AE, will be identified.Timepoint: during the period of 24 th hour and till discharge after drug administration;The disproportionality analysis will identify the new signals for MTX in the population.Timepoint: single time point | — |
Countries
India
Contacts
Public ContactRajesh V
Kasturba medical college
Outcome results
None listed